Checks long-term safety of ianalumab in people with lupus
Tests ianalumab against placebo for long-term safety in people with lupus.
Plain-language title generated from the registry record
Registry title: Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Key facts
- Where
- Beijing, Changchun, Chengdu, Guangzhou, Linyi, Nanchang, Nanjing, Ningbo, Pingxiang, Shanghai, Shantou, Suzhou, Ürümqi, Wenzhou, and Xinxiang, ChinaSee the 15 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with systemic lupus erythematosus who finished the treatment period of one of the two SIRIUS-SLE core studies. It checks long-term safety of ianalumab.
- Age
- 12 Years to 100 Years
- Sex
- All sexes can join.
- Earlier treatment
- Must have taken part in SIRIUS-SLE core study CVAY736F12301 or CVAY736F12302. Must have completed the treatment period through Week 60 without stopping treatment.
Main reasons for not taking part
- Use of prohibited therapies
- Active infection needing intravenous or intramuscular treatment that puts the person at risk
- Plans for live vaccines during the study
- Pregnant or nursing (breastfeeding) women
Read by machine on 10 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 100 years old?
Source: NCT06133972, who can take part
Where in China
- BeijingBeijing, ChinaTaking people
- ChangchunChangchun, ChinaTaking people
- ChengduChengdu, ChinaTaking people
- GuangzhouGuangzhou, ChinaTaking people
- LinyiLinyi, ChinaTaking people
- NanchangNanchang, ChinaNo longer taking part
- NanjingNanjing, ChinaTaking people
- NingboNingbo, ChinaTaking people
- PingxiangPingxiang, ChinaTaking people
- ShanghaiShanghai, ChinaTaking people
- ShantouShantou, ChinaTaking people
- SuzhouSuzhou, ChinaTaking people
- ÜrümqiÜrümqi, ChinaTaking people
- WenzhouWenzhou, ChinaTaking people
- XinxiangXinxiang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT06133972EU 2023-505929-14-00
- Record updated
- 9 November 2026
- Original description
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).Read full original descriptionShow less
A Randomized, Double-blind, Placebo-controlled Extension Study, Followed by a Study Treatment Withdrawal or Open-label Period, to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).
Inclusion: Signed informed consent prior to participation in the extension study. Parent or legal guardian's signed informed consent and child's assent, if appropriate, are required before any assessment is performed for participants <18 years of age. Of note, if the participant reaches age of consent (age as per local law) during the study, they will also need to sign the corresponding study Informed Consent Form (ICF) at the next study visit; Participants must have participated in either one of the two SIRIUS-SLE core studies, CVAY736F12301 or CVAY736F12302, and have completed the treatment period through Week 60 without treatment discontinuation; In the judgement of the investigator, participants must be expected to clinically benefit from continued study treatment.
Exclusion: Use of prohibited therapies; Plans for administration of live vaccines during the study period; Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection which in the opinion of the investigator will place the participant at risk for participation; Pregnant or nursing (lactating) women; Other protocol-defined inclusion/exclusion criteria may apply.